share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A：超過5%持股股東披露文件(修正)-The Vanguard Group(5.40%)
美股SEC公告 ·  2024/11/12 07:36

Moomoo AI 已提取核心訊息

The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 12, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group's clients, including registered investment companies and other managed accounts, are entitled to receive dividends from or proceeds from the sale of these securities. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, nor in connection with any transaction having that purpose or effect.
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 12, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group's clients, including registered investment companies and other managed accounts, are entitled to receive dividends from or proceeds from the sale of these securities. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, nor in connection with any transaction having that purpose or effect.
先鋒集團於2024年11月12日向證券交易委員會提交了修訂的Schedule 13G/A，表明其在bluebird bio, Inc.普通股的持股發生了變化。截止到2024年9月30日，先鋒集團報告其對bluebird bio的有益擁有權爲10,474,007股，佔公司普通股類別的5.40%。該文件顯示，先鋒集團對87,543股擁有共同投票權，對10,330,825股擁有獨佔處置權，並對143,182股擁有額外的共同處置權。先鋒集團的客戶，包括註冊投資公司和其他管理帳戶，有權從這些證券的分紅派息或銷售收益中獲益。該文件聲明這些證券並非爲改變或影響bluebird bio的控制權而收購，也沒有與任何具有該目的或效果的交易相關。
先鋒集團於2024年11月12日向證券交易委員會提交了修訂的Schedule 13G/A，表明其在bluebird bio, Inc.普通股的持股發生了變化。截止到2024年9月30日，先鋒集團報告其對bluebird bio的有益擁有權爲10,474,007股，佔公司普通股類別的5.40%。該文件顯示，先鋒集團對87,543股擁有共同投票權，對10,330,825股擁有獨佔處置權，並對143,182股擁有額外的共同處置權。先鋒集團的客戶，包括註冊投資公司和其他管理帳戶，有權從這些證券的分紅派息或銷售收益中獲益。該文件聲明這些證券並非爲改變或影響bluebird bio的控制權而收購，也沒有與任何具有該目的或效果的交易相關。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間